TRIB3 and atherosclerosis: Finally, using a preclinical mouse model of advanced atherosclerosis, we show that targeting TRIB3 in atheroma could be an attractive therapeutic strategy to improve lesional macrophage efferocytosis efficiency, decrease plaque necrosis, and promote atherosclerotic plaque stabilization.